ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
26 Octobre 2023 - 10:05PM
ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its
quarter ended September 30, 2023.
First Quarter 2024 HighlightsAll comparisons
are to the prior year period
- Revenue increased by
16% to $1.1 billion; up 15% on a constant currency basis
- Gross margin
contracted 250 bps to 54.4%; non-GAAP gross margin
contracted 160 bps to 56.0%
- Income from
operations increased 5%; non-GAAP operating profit up
10%
- Operating cash flow
of $286.3 million
- Diluted earnings per
share of $1.49; non-GAAP diluted earnings per share of
$1.64
“ResMed has started Fiscal Year 2024 with strong revenue growth
driven by ongoing patient flow and solid demand across our global
sleep and respiratory care markets, alongside increasing adoption
of our outside hospital software solutions,” said Mick Farrell,
ResMed’s CEO. “Our ability to meet global demand with technologies,
including our best-in-class AirSense 11 platform, has positioned us
well to continue growing across global markets, with particularly
strong growth this quarter in Europe, Asia, and beyond. We’ve begun
rolling out AI-driven software products into our digital health
ecosystem, which I believe will create a new class of offerings
that will allow us to continue to drive long-term, profitable
growth. New patient starts on our physician and provider-facing
platform, called AirView, and our patient-facing app, called myAir,
show very strong patient flow. With these increasing rates of
patients activated into the healthcare funnel, I am more confident
than ever in our growth strategy and our ability to achieve our
goal of improving 250 million lives in 2025.”
Financial Results and Operating
MetricsUnaudited; $ in millions, except for per share
amounts
|
Three Months Ended |
|
September 30,2023 |
|
September 30,2022 |
|
% Change |
|
ConstantCurrency (A) |
Revenue |
$ |
1,102.3 |
|
|
$ |
950.3 |
|
|
16 |
% |
|
15 |
% |
Gross margin |
|
54.4 |
% |
|
|
56.9 |
% |
|
(4 |
) |
|
|
Non-GAAP gross
margin (B) |
|
56.0 |
% |
|
|
57.6 |
% |
|
(3 |
) |
|
|
Selling, general, and
administrative expenses |
|
222.9 |
|
|
|
193.9 |
|
|
15 |
|
|
14 |
|
Research and development
expenses |
|
75.7 |
|
|
|
63.2 |
|
|
20 |
|
|
21 |
|
Income from operations |
|
289.0 |
|
|
|
275.7 |
|
|
5 |
|
|
|
Non-GAAP income from
operations (B) |
|
318.8 |
|
|
|
290.8 |
|
|
10 |
|
|
|
Net income |
|
219.4 |
|
|
|
210.5 |
|
|
4 |
|
|
|
Non-GAAP net
income (B) |
|
241.2 |
|
|
|
222.1 |
|
|
9 |
|
|
|
Diluted earnings per
share |
$ |
1.49 |
|
|
$ |
1.43 |
|
|
4 |
|
|
|
Non-GAAP diluted earnings
per share (B) |
$ |
1.64 |
|
|
$ |
1.51 |
|
|
9 |
|
|
|
(A) |
In order to provide a framework for assessing how our underlying
businesses performed excluding, the effect of foreign currency
fluctuations, we provide certain financial information on a
“constant currency” basis, which is in addition to the actual
financial information presented. In order to calculate our constant
currency information, we translate the current period financial
information using the foreign currency exchange rates that were in
effect during the previous comparable period. However, constant
currency measures should not be considered in isolation or as an
alternative to U.S. dollar measures that reflect current period
exchange rates, or to other financial measures calculated and
presented in accordance with U.S. GAAP. |
|
|
(B) |
See the reconciliation of non-GAAP financial measures in
the table at the end of the press release. |
|
|
Discussion of First Quarter ResultsAll
comparisons are to the prior year period unless otherwise noted
- Revenue grew by 15 percent on a constant currency basis,
driven by increased demand for our sleep and respiratory care
devices.
- Revenue in the U.S., Canada, and Latin America, excluding
Software-as-a-Service, grew by 10 percent.
- Revenue in Europe, Asia, and other markets, excluding
Software-as-a-Service, grew by 18 percent on a constant
currency basis.
- Software-as-a-Service revenue increased by 32 percent,
reflecting incremental revenue from our acquisition of MEDIFOX DAN
and continued organic growth in our SaaS portfolio.
- Gross margin decreased by 250 basis points
and non-GAAP gross margin decreased by 160 basis points,
mainly due to costs associated with a field safety notification on
Astral devices and higher component and manufacturing costs,
partially offset by a favorable product mix and favorable foreign
currency movements.
- Selling, general, and administrative expenses increased by
14 percent on a constant currency basis. SG&A expenses
improved to 20.2 percent of revenue in the quarter, compared
with 20.4 percent in the same period of the prior year. The
increase in SG&A expenses were mainly due to increases in
employee-related expenses and incremental expense associated with
our acquisition of MEDIFOX DAN.
- Income from operations increased by 5 percent
and non-GAAP income from operations increased by 10
percent.
- Net income for the quarter was $219.4 million and diluted
earnings per share was $1.49. Non-GAAP net income
increased by 9% to $241.2 million, and non-GAAP diluted
earnings per share increased by 9% to $1.64, predominantly
attributable to strong sales, partially offset by gross margin
contraction.
- Operating cash flow for the quarter was $286.3 million,
compared to net income in the current quarter of $219.4 million and
non-GAAP net income of $241.2 million. During the quarter we paid
$70.6 million in dividends.
Other Business and Operational Highlights
- Presented at the European Respiratory Society (ERS) Congress on
topics including improving NIV management, phenotyping, and
personalizing OSA therapy, innovative clinical practice in home
high-flow therapy, indication of use of ASV therapy, and
implementing patient feedback in CPAP therapy management.
- Announced and closed the acquisition of privately held
Somnoware, a leader in digital sleep and respiratory care
diagnostics software for sleep labs and physicians. Somnoware is
upstream of and complementary to ResMed’s current post-testing
AirView and Brightree offerings and will remain an open
platform.
Dividend programThe ResMed board of directors
today declared a quarterly cash dividend of $0.48 per share. The
dividend will have a record date of November 9, 2023, payable
on December 14, 2023. The dividend will be paid in U.S.
currency to holders of ResMed’s common stock trading on the New
York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”)
trading on the Australian Securities Exchange will receive an
equivalent amount in Australian currency, based on the exchange
rate on the record date, and reflecting the 10:1 ratio between CDIs
and NYSE shares. The ex-dividend date will be
November 8, 2023, for common stockholders and for CDI holders.
ResMed has received a waiver from the ASX’s settlement operating
rules, which will allow ResMed to defer processing conversions
between its common stock and CDI registers from November 8,
2023, through November 9, 2023, inclusive.
Webcast detailsResMed will discuss its
first-quarter fiscal year 2024 results on its webcast at 1:30 p.m.
U.S. Pacific Time today. The live webcast of the call can be
accessed on ResMed’s Investor Relations website at
investor.resmed.com. Please go to this section of the website and
click on the icon for the “Q1 2024 Earnings Webcast” to register
and listen to the live webcast. A replay of the earnings webcast
will be accessible on the website and available approximately two
hours after the live webcast. In addition, a telephone replay of
the conference call will be available approximately three hours
after the webcast by dialing +1 877-660-6853 (U.S.) or
+1 201-612-7415 (outside U.S.) and entering the passcode
13741866. The telephone replay will be available until November 9,
2023.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
Safe harbor statementStatements contained in
this release that are not historical facts are “forward-looking”
statements as contemplated by the Private Securities Litigation
Reform Act of 1995. These forward-looking statements – including
statements regarding ResMed’s projections of future revenue or
earnings, expenses, new product development, new product launches,
new markets for its products, the integration of acquisitions, our
supply chain, domestic and international regulatory developments,
litigation, tax outlook, and macroeconomic conditions of our
business – are subject to risks and uncertainties, which could
cause actual results to materially differ from those projected or
implied in the forward-looking statements. Additional risks and
uncertainties are discussed in ResMed’s periodic reports on file
with the U.S. Securities & Exchange Commission. ResMed
does not undertake to update its forward-looking statements.
Condensed Consolidated Statements of
Operations(Unaudited; $ in thousands, except for per share
amounts)
|
Three Months Ended |
|
September 30,2023 |
|
September 30,2022 |
|
|
|
|
Net revenue |
$ |
1,102,321 |
|
|
$ |
950,294 |
|
|
|
|
|
Cost of sales |
|
485,442 |
|
|
|
403,110 |
|
Amortization of acquired
intangibles (1) |
|
8,908 |
|
|
|
6,374 |
|
Astral field safety
notification expenses (1) |
|
7,911 |
|
|
|
— |
|
Total cost of sales |
$ |
502,261 |
|
|
$ |
409,484 |
|
Gross profit |
$ |
600,060 |
|
|
$ |
540,810 |
|
|
|
|
|
Selling, general, and
administrative |
|
222,874 |
|
|
|
193,933 |
|
Research and development |
|
75,710 |
|
|
|
63,188 |
|
Amortization of acquired
intangibles (1) |
|
12,479 |
|
|
|
7,950 |
|
Total operating expenses |
$ |
311,063 |
|
|
$ |
265,071 |
|
Income from operations |
$ |
288,997 |
|
|
$ |
275,739 |
|
|
|
|
|
Other income (expenses),
net: |
|
|
|
Interest income (expense),
net |
$ |
(14,957 |
) |
|
$ |
(7,134 |
) |
Loss attributable to equity
method investments |
|
(3,895 |
) |
|
|
(2,028 |
) |
Gain (loss) on equity
investments (1) |
|
(602 |
) |
|
|
(3,280 |
) |
Other, net |
|
2,648 |
|
|
|
(1,504 |
) |
Total other income (expenses),
net |
|
(16,806 |
) |
|
|
(13,946 |
) |
Income before income
taxes |
$ |
272,191 |
|
|
$ |
261,793 |
|
Income taxes |
|
52,769 |
|
|
|
51,315 |
|
Net income |
$ |
219,422 |
|
|
$ |
210,478 |
|
|
|
|
|
Basic earnings per share |
$ |
1.49 |
|
|
$ |
1.44 |
|
Diluted earnings per
share |
$ |
1.49 |
|
|
$ |
1.43 |
|
Non-GAAP diluted earnings
per share (1) |
$ |
1.64 |
|
|
$ |
1.51 |
|
|
|
|
|
Basic shares outstanding |
|
147,075 |
|
|
|
146,431 |
|
Diluted shares
outstanding |
|
147,486 |
|
|
|
147,134 |
|
(1) |
See the reconciliation of non-GAAP financial measures in
the table at the end of the press release. |
|
|
Condensed Consolidated Balance
Sheets(Unaudited; $ in thousands)
|
September 30,2023 |
|
June 30,2023 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
209,100 |
|
|
$ |
227,891 |
|
Accounts receivable, net |
|
692,388 |
|
|
|
704,909 |
|
Inventories |
|
958,233 |
|
|
|
998,012 |
|
Prepayments and other current assets |
|
444,864 |
|
|
|
437,018 |
|
Total current assets |
$ |
2,304,585 |
|
|
$ |
2,367,830 |
|
Non-current assets: |
|
|
|
Property, plant, and equipment, net |
$ |
533,985 |
|
|
$ |
537,856 |
|
Operating lease right-of-use assets |
|
123,416 |
|
|
|
127,955 |
|
Goodwill and other intangibles, net |
|
3,375,420 |
|
|
|
3,322,640 |
|
Deferred income taxes and other non-current assets |
|
403,380 |
|
|
|
395,427 |
|
Total non-current assets |
$ |
4,436,201 |
|
|
$ |
4,383,878 |
|
Total assets |
$ |
6,740,786 |
|
|
$ |
6,751,708 |
|
Liabilities and
Stockholders’ Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
177,048 |
|
|
$ |
150,756 |
|
Accrued expenses |
|
348,263 |
|
|
|
365,660 |
|
Operating lease liabilities, current |
|
21,795 |
|
|
|
21,919 |
|
Deferred revenue |
|
146,718 |
|
|
|
138,072 |
|
Income taxes payable |
|
67,073 |
|
|
|
72,224 |
|
Short-term debt |
|
9,905 |
|
|
|
9,902 |
|
Total current liabilities |
$ |
770,802 |
|
|
$ |
758,533 |
|
Non-current liabilities: |
|
|
|
Deferred revenue |
$ |
121,492 |
|
|
$ |
119,186 |
|
Deferred income taxes |
|
87,672 |
|
|
|
90,650 |
|
Operating lease liabilities, non-current |
|
112,448 |
|
|
|
116,853 |
|
Other long-term liabilities |
|
34,328 |
|
|
|
68,166 |
|
Long-term debt |
|
1,351,511 |
|
|
|
1,431,234 |
|
Long-term income taxes payable |
|
12,157 |
|
|
|
37,183 |
|
Total non-current liabilities |
$ |
1,719,608 |
|
|
$ |
1,863,272 |
|
Total liabilities |
$ |
2,490,410 |
|
|
$ |
2,621,805 |
|
Stockholders’ equity |
|
|
|
Common stock |
$ |
588 |
|
|
$ |
588 |
|
Additional paid-in capital |
|
1,791,351 |
|
|
|
1,772,083 |
|
Retained earnings |
|
4,401,841 |
|
|
|
4,253,016 |
|
Treasury stock |
|
(1,623,256 |
) |
|
|
(1,623,256 |
) |
Accumulated other comprehensive income |
|
(320,148 |
) |
|
|
(272,528 |
) |
Total stockholders’
equity |
$ |
4,250,376 |
|
|
$ |
4,129,903 |
|
Total liabilities and
stockholders’ equity |
$ |
6,740,786 |
|
|
$ |
6,751,708 |
|
Condensed Consolidated Statements of Cash
Flows(Unaudited; $ in thousands)
|
Three Months Ended |
|
September 30,2023 |
|
September 30,2022 |
Cash flows from
operating activities: |
|
|
|
Net income |
$ |
219,422 |
|
|
$ |
210,478 |
|
Adjustment to reconcile net
income to cash provided by operating activities: |
|
|
|
Depreciation and
amortization |
|
44,934 |
|
|
|
36,273 |
|
Amortization
of right-of-use assets |
|
8,508 |
|
|
|
7,761 |
|
Stock-based compensation
costs |
|
18,510 |
|
|
|
16,919 |
|
Loss attributable to equity
method investments, net of dividends received |
|
3,895 |
|
|
|
2,028 |
|
(Gain) loss on equity
investment |
|
602 |
|
|
|
3,280 |
|
Changes in operating assets
and liabilities: |
|
|
|
Accounts receivable, net |
|
6,534 |
|
|
|
(56,238 |
) |
Inventories, net |
|
26,911 |
|
|
|
(147,096 |
) |
Prepaid expenses, net deferred
income taxes and other current assets |
|
(42,015 |
) |
|
|
(36,784 |
) |
Accounts payable, accrued
expenses, income taxes payable and other |
|
(1,018 |
) |
|
|
8,041 |
|
Net cash provided by operating
activities |
$ |
286,283 |
|
|
$ |
44,662 |
|
Cash flows from
investing activities: |
|
|
|
Purchases of property, plant,
and equipment |
|
(30,035 |
) |
|
|
(29,056 |
) |
Patent registration and
acquisition costs |
|
(10,831 |
) |
|
|
(3,317 |
) |
Business acquisitions, net of
cash acquired |
|
(103,183 |
) |
|
|
(19,100 |
) |
Purchases of investments |
|
(3,680 |
) |
|
|
(4,291 |
) |
Proceeds from exits of
investments |
|
250 |
|
|
|
— |
|
(Payments) / proceeds on
maturity of foreign currency contracts |
|
(1,501 |
) |
|
|
(3,042 |
) |
Net cash used in investing
activities |
$ |
(148,980 |
) |
|
$ |
(58,806 |
) |
Cash flows from
financing activities: |
|
|
|
Proceeds from issuance of
common stock, net |
|
983 |
|
|
|
2,610 |
|
Taxes paid related to net
share settlement of equity awards |
|
(225 |
) |
|
|
(59 |
) |
Payments of business
combination contingent consideration |
|
(1,293 |
) |
|
|
— |
|
Proceeds from borrowings, net
of borrowing costs |
|
105,000 |
|
|
|
50,000 |
|
Repayment of borrowings |
|
(185,000 |
) |
|
|
(30,000 |
) |
Dividends paid |
|
(70,597 |
) |
|
|
(64,431 |
) |
Net cash (used in) / provided
by financing activities |
$ |
(151,132 |
) |
|
$ |
(41,880 |
) |
Effect of exchange rate
changes on cash |
$ |
(4,962 |
) |
|
$ |
(10,523 |
) |
Net increase / (decrease) in
cash and cash equivalents |
|
(18,791 |
) |
|
|
(66,547 |
) |
Cash and cash equivalents at
beginning of period |
|
227,891 |
|
|
|
273,710 |
|
Cash and cash
equivalents at end of period |
$ |
209,100 |
|
|
$ |
207,163 |
|
Reconciliation of Non-GAAP Financial
Measures(Unaudited; $ in thousands, except for per share
amounts)
The measures “non-GAAP gross profit”
and “non-GAAP gross margin” exclude amortization expense
from acquired intangibles and restructuring expense related to cost
of sales and are reconciled below:
|
Three Months Ended |
|
September 30, 2023 |
|
September 30, 2022 |
|
|
|
|
Revenue |
$ |
1,102,321 |
|
|
$ |
950,294 |
|
|
|
|
|
GAAP cost of sales |
$ |
502,261 |
|
|
$ |
409,484 |
|
Less: Amortization of
acquired intangibles (A) |
|
(8,908 |
) |
|
|
(6,374 |
) |
Less: Astral field safety
notification expenses (A) |
|
(7,911 |
) |
|
|
— |
|
Non-GAAP cost of
sales |
$ |
485,442 |
|
|
$ |
403,110 |
|
|
|
|
|
GAAP gross profit |
$ |
600,060 |
|
|
$ |
540,810 |
|
GAAP gross margin |
|
54.4 |
% |
|
|
56.9 |
% |
Non-GAAP gross
profit |
$ |
616,879 |
|
|
$ |
547,184 |
|
Non-GAAP gross
margin |
|
56.0 |
% |
|
|
57.6 |
% |
The measure “non-GAAP income from operations” is
reconciled with GAAP income from operations below:
|
Three Months Ended |
|
September 30, 2023 |
|
September 30, 2022 |
|
|
|
|
GAAP income from operations |
$ |
288,997 |
|
|
$ |
275,739 |
|
Amortization of acquired
intangibles—cost of sales (A) |
|
8,908 |
|
|
|
6,374 |
|
Amortization of acquired
intangibles—operating expenses (A) |
|
12,479 |
|
|
|
7,950 |
|
Acquisition-related
expenses (A) |
|
483 |
|
|
|
745 |
|
Astral field safety
notification expenses (A) |
|
7,911 |
|
|
|
— |
|
Non-GAAP income from
operations |
$ |
318,778 |
|
|
$ |
290,808 |
|
Reconciliation of Non-GAAP Financial
Measures(Unaudited; $ in thousands, except for per share
amounts)
The measures “non-GAAP net income”
and “non-GAAP diluted earnings per share” are reconciled
with GAAP net income and GAAP diluted earnings per share in the
table below:
|
Three Months Ended |
|
September 30, 2023 |
|
September 30, 2022 |
|
|
|
|
GAAP net income |
$ |
219,422 |
|
|
$ |
210,478 |
|
Amortization of acquired
intangibles—cost of sales (A) |
|
8,908 |
|
|
|
6,374 |
|
Amortization of acquired
intangibles—operating expenses (A) |
|
12,479 |
|
|
|
7,950 |
|
Acquisition-related
expenses (A) |
|
483 |
|
|
|
745 |
|
Astral field safety
notification expenses (A) |
|
7,911 |
|
|
|
— |
|
Income tax effect on non-GAAP
adjustments (A) |
|
(8,019 |
) |
|
|
(3,458 |
) |
Non-GAAP net
income (A) |
$ |
241,184 |
|
|
$ |
222,089 |
|
|
|
|
|
GAAP diluted shares
outstanding |
|
147,486 |
|
|
|
147,134 |
|
GAAP diluted earnings per
share |
$ |
1.49 |
|
|
$ |
1.43 |
|
Non-GAAP diluted earnings
per share (A) |
$ |
1.64 |
|
|
$ |
1.51 |
|
(A) |
ResMed adjusts for the impact of the amortization of acquired
intangibles, acquisition-related expenses, Astral field safety
notification expenses, and associated tax effects from their
evaluation of ongoing operations, and believes that investors
benefit from adjusting these items to facilitate a more meaningful
evaluation of current operating performance.ResMed believes
that non-GAAP diluted earnings per share is an additional
measure of performance that investors can use to compare operating
results between reporting periods. ResMed
uses non-GAAP information internally in planning,
forecasting, and evaluating the results of operations in the
current period and in comparing it to past periods. ResMed believes
this information provides investors better insight when evaluating
ResMed’s performance from core operations and provides consistent
financial reporting. The use of non-GAAP measures is
intended to supplement, and not to replace, the presentation of net
income and other GAAP measures. Like
all non-GAAP measures, non-GAAP earnings are
subject to inherent limitations because they do not include all the
expenses that must be included under GAAP. |
|
|
Revenue by Product and Region(Unaudited; $ in
millions, except for per share amounts)
|
Three Months Ended |
|
September 30,2023 |
(A) |
September 30,2022 |
(A) |
% Change |
|
ConstantCurrency (B) |
U.S., Canada, and
Latin America |
|
|
|
|
|
|
|
Devices |
$ |
345.9 |
|
$ |
339.5 |
|
2 |
% |
|
|
Masks and other |
|
292.5 |
|
|
238.6 |
|
23 |
|
|
|
Total U.S., Canada and Latin
America |
$ |
638.4 |
|
$ |
578.1 |
|
10 |
|
|
|
|
|
|
|
|
|
|
|
Combined Europe, Asia,
and other markets |
|
|
|
|
|
|
|
Devices |
$ |
218.8 |
|
$ |
178.0 |
|
23 |
% |
|
20 |
% |
Masks and other |
|
105.8 |
|
|
88.3 |
|
20 |
|
|
15 |
|
Total Combined Europe, Asia
and other markets |
$ |
324.7 |
|
$ |
266.3 |
|
22 |
|
|
18 |
|
|
|
|
|
|
|
|
|
Global
revenue |
|
|
|
|
|
|
|
Total Devices |
$ |
564.7 |
|
$ |
517.6 |
|
9 |
% |
|
8 |
% |
Total Masks and other |
|
398.3 |
|
|
326.9 |
|
22 |
|
|
21 |
|
Total Sleep and
Respiratory Care |
$ |
963.0 |
|
$ |
844.4 |
|
14 |
|
|
13 |
|
|
|
|
|
|
|
|
|
Software-as-a-Service |
|
139.3 |
|
|
105.9 |
|
32 |
|
|
|
Total |
$ |
1,102.3 |
|
$ |
950.3 |
|
16 |
|
|
15 |
|
|
|
|
|
|
|
|
|
(A) |
Totals and subtotals may not add due to rounding. |
|
|
(B) |
In order to provide a framework for assessing how our underlying
businesses performed excluding the effect of foreign currency
fluctuations, we provide certain financial information on a
“constant currency basis,” which is in addition to the actual
financial information presented. In order to calculate our constant
currency information, we translate the current period financial
information using the foreign currency exchange rates that were in
effect during the previous comparable period. However, constant
currency measures should not be considered in isolation or as an
alternative to U.S. dollar measures that reflect current period
exchange rates, or to other financial measures calculated and
presented in accordance with U.S. GAAP. |
|
|
For investors |
For media |
+1 858-836-5000 |
+1 858-289-7272 |
investorrelations@resmed.com |
news@resmed.com |
ResMed (NYSE:RMD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
ResMed (NYSE:RMD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024